(RTTNews) - Lipocine Inc.'s (LPCN) Tlando, an oral testosterone product, which failed to get the FDA nod thrice, has finally passed muster.

Did LPCN get FDA approval?

LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA.

Should I buy LPCN stock?

Out of 3 analysts, 2 (66.67%) are recommending LPCN as a Strong Buy, 1 (33.33%) are recommending LPCN as a Buy, 0 (0%) are recommending LPCN as a Hold, 0 (0%) are recommending LPCN as a Sell, and 0 (0%) are recommending LPCN as a Strong Sell. What is LPCN's earnings growth forecast for 2021-2023?